Skip Navigation U.S. Department of Health and Human Services www.hhs.gov/
Agency for Healthcare Research Quality www.ahrq.gov
www.ahrq.gov/

Director's Update


Attention-Deficit/Hyperactivity Disorder (ADHD) Medications and Risk of Serious Cardiovascular Events in Adults

Text Description is below the image.

  • AHRQ and Food and Drug Administration (FDA) study of 440,000 adults aged 25-64 years, including over 150,000 adults treated with medications for ADHD.
  • Assessed myocardial infarction, stroke, and sudden cardiac death.
  • Use of ADHD medications was not associated with an increased risk of serious cardiovascular events:
    • The result is consistent with the research team's early publication in NEJM, which found no evidence of cardiovacular risk of ADHD drugs among children and young adults.
  • New study from Effective Health Care Program's Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network in JAMA.

Habel LA, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA 2011 Dec 28;306(24):2673-83. Epub 2011 Dec 12.

Image: The first page of the cited JAMA article is shown.


Previous Slide Previous Slide         Contents         Next Slide Next Slide


 

AHRQAdvancing Excellence in Health Care